Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Saudi viewers angry over apparent ban on World Cup streaming
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Saudi viewers angry over apparent ban on World Cup streaming
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Saudi viewers angry over apparent ban on World Cup streaming
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
THE BEST BLACK FRIDAY DEAL YET (Ad)
Whole Foods decision to pull lobster divides enviros, pols
Airbnb has a plan to fix cleaning fees
THE BEST BLACK FRIDAY DEAL YET (Ad)
Railway workers in Austria to strike Monday in pay standoff
Saudi viewers angry over apparent ban on World Cup streaming
NASDAQ:HSKA

Heska - HSKA Stock Forecast, Price & News

$62.15
-0.73 (-1.16%)
(As of 11/25/2022 04:00 PM ET)
Add
Compare
Today's Range
$61.76
$63.80
50-Day Range
$62.15
$85.99
52-Week Range
$58.00
$189.37
Volume
37,053 shs
Average Volume
91,047 shs
Market Capitalization
$673.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$142.25

Heska MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
128.9% Upside
$142.25 Price Target
Short Interest
Bearish
10.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
162.96%
From $0.27 to $0.71 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

570th out of 1,044 stocks

Diagnostic Substances Industry

5th out of 15 stocks

HSKA stock logo

About Heska (NASDAQ:HSKA) Stock

Heska Corporation sells veterinary and animal health diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; and turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force, and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was founded in 1988 and is based in Loveland, Colorado.

Receive HSKA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heska and its competitors with MarketBeat's FREE daily newsletter.

HSKA Stock News Headlines

Heska Corporation Reports Third Quarter 2022 Results
Heska (HSKA) Q3 Earnings and Revenues Lag Estimates
Piper Sandler Raises Heska (NASDAQ:HSKA) Price Target to $170.00
See More Headlines
Receive HSKA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heska and its competitors with MarketBeat's FREE daily newsletter.

HSKA Company Calendar

Last Earnings
11/04/2021
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HSKA
Employees
655
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$142.25
High Stock Price Forecast
$165.00
Low Stock Price Forecast
$119.00
Forecasted Upside/Downside
+128.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-1,150,000.00
Pretax Margin
-7.34%

Debt

Sales & Book Value

Annual Sales
$253.74 million
Cash Flow
$1.05 per share
Book Value
$37.68 per share

Miscellaneous

Free Float
9,635,000
Market Cap
$673.08 million
Optionable
Not Optionable
Beta
1.45

Key Executives

  • Mr. Kevin S. WilsonMr. Kevin S. Wilson (Age 50)
    CEO, Pres & Director
    Comp: $1.84M
  • Ms. Catherine I. Grassman CPAMs. Catherine I. Grassman CPA (Age 46)
    Exec. VP & CFO
    Comp: $583.3k
  • Dr. Nancy Wisnewski (Age 59)
    Exec. VP & COO
    Comp: $581.23k
  • Mr. Christopher D. Sveen (Age 39)
    EVP, Chief Admn. Officer, Gen. Counsel, Corp. Sec. & Pres of Diamond Animal Health
    Comp: $536.41k
  • Mr. Steven M. Eyl (Age 56)
    Exec. VP, Chief Commercial Officer & Pres of scil animal care company
    Comp: $587.63k
  • Mr. Jon Aagaard
    Director of Investor Relations
  • Mr. Anthony C. Providenti Jr. (Age 55)
    Exec. VP of Corp. Devel.
  • Ms. Eleanor F. Baker (Age 37)
    Exec. VP, MD & COO of scil animal care company
  • Daniel J. Pollack
    VP of Imaging Operations, Treasurer & Assistant Sec.
  • Laurie E. Peterson
    VP of Heska Des Moines













HSKA Stock - Frequently Asked Questions

Should I buy or sell Heska stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heska in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HSKA shares.
View HSKA analyst ratings
or view top-rated stocks.

What is Heska's stock price forecast for 2023?

4 equities research analysts have issued 12-month target prices for Heska's stock. Their HSKA share price forecasts range from $119.00 to $165.00. On average, they expect the company's share price to reach $142.25 in the next twelve months. This suggests a possible upside of 128.9% from the stock's current price.
View analysts price targets for HSKA
or view top-rated stocks among Wall Street analysts.

How have HSKA shares performed in 2022?

Heska's stock was trading at $182.49 at the beginning of the year. Since then, HSKA shares have decreased by 65.9% and is now trading at $62.15.
View the best growth stocks for 2022 here
.

When is Heska's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our HSKA earnings forecast
.

How were Heska's earnings last quarter?

Heska Co. (NASDAQ:HSKA) issued its quarterly earnings results on Thursday, November, 4th. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by $0.23. The medical research company earned $60.24 million during the quarter, compared to the consensus estimate of $63.80 million. Heska had a positive trailing twelve-month return on equity of 0.09% and a negative net margin of 6.26%. The firm's revenue for the quarter was up 6.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.25) EPS.

What guidance has Heska issued on next quarter's earnings?

Heska issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $266.43 million-$266.43 million, compared to the consensus revenue estimate of $272.89 million.

What is Kevin S. Wilson's approval rating as Heska's CEO?

5 employees have rated Heska Chief Executive Officer Kevin S. Wilson on Glassdoor.com. Kevin S. Wilson has an approval rating of 57% among the company's employees. This puts Kevin S. Wilson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Heska own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Gilead Sciences (GILD), Exxon Mobil (XOM), Netflix (NFLX), Biogen (BIIB), AbbVie (ABBV), Amgen (AMGN), Broadcom (AVGO), Alibaba Group (BABA), Exelixis (EXEL) and Merck & Co., Inc. (MRK).

What is Heska's stock symbol?

Heska trades on the NASDAQ under the ticker symbol "HSKA."

Who are Heska's major shareholders?

Heska's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.59%), Vanguard Group Inc. (6.55%), Fred Alger Management LLC (5.44%), State Street Corp (3.57%), Riverbridge Partners LLC (3.00%) and Grandeur Peak Global Advisors LLC (2.33%). Insiders that own company stock include Bonnie J Trowbridge, Catherine Grassman, Jason D Aroesty, Kevin S Wilson, Nancy Wisnewski and Sharon J Larson.
View institutional ownership trends
.

How do I buy shares of Heska?

Shares of HSKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Heska's stock price today?

One share of HSKA stock can currently be purchased for approximately $62.15.

How much money does Heska make?

Heska (NASDAQ:HSKA) has a market capitalization of $673.08 million and generates $253.74 million in revenue each year. The medical research company earns $-1,150,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis.

How many employees does Heska have?

The company employs 655 workers across the globe.

How can I contact Heska?

Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The official website for the company is www.heska.com. The medical research company can be reached via phone at (970) 493-7272, via email at investorrelations@heska.com, or via fax at 970-619-3003.

This page (NASDAQ:HSKA) was last updated on 11/27/2022 by MarketBeat.com Staff